Scworx Corp

Scworx Corp(WORX)股票分析

$2.190

-0.352 (-16.09%)收盤時

Loading chart…
最高
2.660
開盤
2.570
成交量加權均價
2.34
成交量
442.65K
市值
2.08M
最低
2.180
成交金額
1.04M
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

SCWorx Corp. is a provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. The Company has developed and markets health care information technology solutions and associated services that enhance healthcare processes and information flow within hospitals and other healthcare facilities. Its software enables a healthcare provider to simplify and organize its data (data normalization), allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics (big data). Its software modules include virtualized item master file repair, expansion and automation, electronic medical record management, charge description master management, contract management, request for proposal (RFP) automation, integration of acquired businesses, rebate management, and data integration and warehousing.

AI 分析 of Scworx Corp (WORX)

賣出

Worx Corp is not a good buy right now due to significant declines in stock performance and negative financial indicators. The current price is $1.38, which is down 96.22% year-to-date, indicating severe underperformance. Additionally, the RSI is at an extremely low level of 5.451, suggesting that the stock is oversold, but this could also indicate a lack of buying interest. The forward P/E ratio is 0, reflecting no expected earnings growth, and the gross margin, while improving to 46.67% in Q2 2026, is overshadowed by a net margin of -17.13%. The main risk is the substantial 94.04% decline over the past 20 days, indicating a strong downward trend.

估值指標

Scworx Corp(WORX)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 WORX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%WORX

$0.50

情境價格

基

基準

基準 · 50%WORX

$0.50

情境價格

悲

悲觀

悲觀 · 25%WORX

$0.42

情境價格

事件時間軸

2026-10-19 (ET)

10:30:00

SCWorx Enters New Agreement with Community Healthcare System

2026-10-08 (ET)

12:30:00

Scworx Corp Trading Halted Due to Volatility

12:30:00

Scworx Corp Trading Resumes

2026-10-05 (ET)

13:30:00

SCWorx Granted Continued Listing on Nasdaq

2026-08-06 (ET)

11:30:00

SCWorx Signs Two-Year Agreement with Major Massachusetts Healthcare Network

資訊

WORX 常見問題 —— 由 Alphio AI 解答

SCWorx Corp. is a provider of data content and services related to the repair, normalization and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. The Company has developed and markets health care information technology solutions and associated services that enhance healthcare processes and information flow within hospitals and other healthcare facilities. Its software enables a healthcare provider to simplify and organize its data (data normalization), allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics (big data). Its software modules include virtualized item master file repair, expansion and automation, electronic medical record management, charge description master management, contract management, request for proposal (RFP) automation, integration of acquired businesses, rebate management, and data integration and warehousing. It operates in the Industrials sector (SERVICES-MISCELLANEOUS AMUSEMENT & RECREATION industry).

Worx Corp is not a good buy right now due to significant declines in stock performance and negative financial indicators. The current price is $1.38, which is down 96.22% year-to-date, indicating severe underperformance. Additionally, the RSI is at an extremely low level of 5.451, suggesting that the stock is oversold, but this could also indicate a lack of buying interest. The forward P/E ratio is 0, reflecting no expected earnings growth, and the gross margin, while improving to 46.67% in Q2 2026, is overshadowed by a net margin of -17.13%. The main risk is the substantial 94.04% decline over the past 20 days, indicating a strong downward trend.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易